WC
IBB icon

Wexford Capital’s iShares Biotechnology ETF IBB Stock Holding History

Wexford Capital’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,765
Closed -$1.65M – 272
2025
Q4 		$1.65M Buy
+9,765
New +$1.59M 0.32% 52
2018
Q4 		– Sell
-27,962
Closed -$3.41M – 109
2018
Q3 		$3.41M Buy
+27,962
New +$3.29M 0.22% 50
2016
Q4 		– Sell
-46,368
Closed -$4.47M – 274
2016
Q3 		$4.47M Buy
+46,368
New +$4.41M 0.73% 42
2015
Q3 		– Sell
-93,213
Closed -$11.5M – 90
2015
Q2 		$11.5M Buy
93,213
+37,782
+68% +$4.52M 3.06% 7
2015
Q1 		$6.35M Buy
55,431
+4,881
+10% +$538K 1.85% 14
2014
Q4 		$5.11M Buy
+50,550
New +$4.91M 0.98% 17

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Wexford Capital's IBB Position: Q1 2026 in Review

Wexford Capital sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 9,765 shares — an estimated $1.65M sold.

Wexford Capital first reported a position in IBB in Q4 2014 and held it in 6 quarters. The position peaked at $11.5M in Q2 2015. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Wexford Capital reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
  • Wexford Capital sold 9,765 iShares Biotechnology ETF shares in Q1 2026, an estimated $1.65M.
  • Wexford Capital first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 6 quarters.
  • Wexford Capital's iShares Biotechnology ETF position peaked at $11.5M in Q2 2015.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.